New drug aims to tame dangerous phosphate levels in dialysis patients
NCT ID NCT06712654
First seen May 15, 2026 · Last updated May 23, 2026 · Updated 2 times
Summary
This study tests a new medicine called AP306 to see if it can safely lower high phosphate levels in adults with kidney failure who are on dialysis. High phosphate is a common problem that can lead to bone and heart issues. About 168 participants will receive either AP306 or a placebo to measure how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE REQUIRING CHRONIC DIALYSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Academic Medical Research Institute
Los Angeles, California, 90022, United States
-
Apogee Clinical Research, LLC
Huntsville, Alabama, 35801, United States
-
California Institute of Renal Research
Chula Vista, California, 91910, United States
-
Colorado Kidney Care
Denver, Colorado, 80220, United States
-
DaVita Clinical Research
Middlebury, Connecticut, 06762, United States
-
DaVita Clinical Research
Las Vegas, Nevada, 89107, United States
-
DaVita Clinical Research
Houston, Texas, 77054, United States
-
DaVita Clinical Research
San Antonio, Texas, 78258, United States
-
DaVita Clinical Research
Norfolk, Virginia, 23502, United States
-
Gamma Medical Research
McAllen, Texas, 78503, United States
-
Johnson County Clinical Trials
Kansas City, Missouri, 64111, United States
-
Peking University First Hospital
Beijing, Beijing Municipality, 100035, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, 100044, China
-
Renal Medicines Associates
Albuquerque, New Mexico, 87109, United States
-
Shanghai Jiao Tong University School of Medicine, Renji Hospital
Shanghai, Shanghai Municipality, 201112, China
-
Sichuan Provincial People's Hospital
Chengdu, Sichuan, 610072, China
-
St. Clair Nephrology Research
Shelby, Michigan, 48315, United States
-
Sunbeam Research
Greenville, Texas, 75402, United States
-
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, 210003, China
-
US Renal Care
Orange, Connecticut, 06477, United States
-
US Renal Care
Fort Myers, Florida, 33912, United States
-
US Renal Care
Dalton, Georgia, 30720, United States
-
US Renal Care
Toledo, Ohio, 43613, United States
-
US Renal Care
San Antonio, Texas, 78251, United States
-
Zhengzhou University-First Affiliated Hospital
Zhengzhou, Henan, 450003, China
-
Zhongda Hospital Southeast University
Nanjing, Jiangsu, 210009, China
Conditions
Explore the condition pages connected to this study.